Clashing ideologies or scientific discourse?

Schizophrenia Bulletin

Volumn 28, Issue 4, 2002, Pages 583-588

  Bola, John R ^a   Mosher, Loren R ^b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Soteria Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DRUG INDUCED DISEASE; HUMAN; INDIVIDUALIZATION; LONG TERM CARE; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; NATIONAL HEALTH SERVICE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; PSYCHOSOCIAL CARE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN;

EID: 0038327563     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006966     Document Type: Review

References (38)

1. Andreasen, N.C. Understanding schizophrenia: A silent spring? American Journal of Psychiatry, 155(12):1657-1659, 1998.
2. Baptista, T. Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatrica Scandinavica, 100(1):3-16, 1999.
3. Bola, J.R., and Mosher, L.R. Predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophrenia Bulletin, 28(4):559-575, 2002.
4. Carpenter, W.T. The risk of medication-free research. Schizophrenia Bulletin, 23(1):11-18, 1997.
5. Carpenter, W.T., and Buchanan, R.W. Commentary on the Soteria project: Misguided therapeutics. Schizophrenia Bulletin, 28(4):577-581, 2002.
6. Carpenter, W.T., and Heinrichs, D.W. Treatment-relevant subtypes of schizophrenia. Journal of Nervous and Mental Disease, 169(2):113-119, 1981.
7. Carpenter, W.T.; McGlashan, T.H.; and Strauss, J.S. The treatment of acute schizophrenia without drugs: An investigation of some current assumptions. American Journal of Psychiatry, 134(1):14-20, 1977.
8. Carpenter, W.T.; Schooler, N.R.; and Kane, J.M. The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry, 45(5):401-407, 1997.
9. Ciompi, L.; Duwalder, H.-P.; Maier, C.; Aebi, E.; Trutsch, K.; Kupper, Z.; and Rutishauser, C. The pilot project "Soteria Berne": Clinical experiences and results. British Journal of Psychiatry, 161(Suppl 18):145-153, 1992.
10. Ciompi, L.; Kupper, Z.; Aebi, E.; Duwalder, H.P.; Hubschmidt, T.; Trutsch, K.; and Ruitshauser, C. Da Pilot-Projekt "Soteria Bern" zur behandlung akut schizophener: II. Ergebnisse der vergleichenden prospektiven verlaufsstudie uber zwei jahre. [The pilot project "Soteria Bern" in treatment of acute schizophrenia patients: II. Results of a comparative prospective follow-up period over 2 years.] Der Nervenarzt, 64:440-450, 1993.
11. Cole, J.O.; Klerman, G.L.; Goldberg, S.C.; and the NIMHPSC Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10:246-261, 1964.
12. Cronbach, L.J., and Snow, R.E. Aptitudes and Instructional Methods: A Handbook for Research on Interactions. New York, NY: John Wiley and Sons, 1977.
13. Crow, T.J.; Owens, D.G.; Johnstone, E.C.; Cross, A.J.; and Owen, F. Does tardive dyskinesia exist? Modern Problems of Pharmacopsychiatry, 21:206-219, 1983.
14. Fenton, W.S.; Blyler, C.R.; and Heinssen, R.K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4):637-651, 1997.
15. Fisher, D.; Beutler, L.E.; and Williams, O.B. Making assessment relevant to treatment planning: The STS clinician rating form. Journal of Consulting and Clinical Psychology, 55:825-842, 1999.
16. Guze, S.B. The future of psychiatry: Medicine or social science? Journal of Nervous and Mental Disease, 165(4):225-230, 1977.
17. Haynes, S.N.; Kaholokula, J.K.; and Nelson, K. The ideographic application of nomothetic, empirically based treatments. Clinical Psychology: Science and Practice, 6(4):456-461, 1999.
18. Hellewell, J.S. Treatment-resistant schizophrenia: Reviewing the options and identifying the way forward. Journal of Clinical Psychiatry, 60(Suppl 23):14-19, 1999.
19. Kendell, R.E. Clinical Validity: The Validity of Psychiatric Diagnosis. New York, NY: Raven Press, 1989.
20. Lehman, A.F., and Steinwachs, D.M. The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24(1):1-10, 1998.
21. Lehtinen, V.; Aaltonen, J.; Koffert, T.; Rakkolainen, V.; and Syvalahti, E. Two-year outcome in first-episode psychosis treated according to an integrated model: Is immediate neuroleptisation always needed? European Psychiatry, 15(5):312-320, 2000.
22. Leshner, A.I., and Burke, J.D. Foreword. Caring for People with Severe Mental Disorders: A National Plan for Research to Improve Services. DHHS Pub. No. (ADM) 91-1762. Washington, DC: National Institute of Mental Health, 1991.
23. Lieberman, J.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. Journal of Clinical Psychiatry, 57(Suppl 11):68-71, 1996.
24. Madsen, A.L.; Keidling, N.; Karle, A.; Esbjerg, S.; and Hemmingsen, R. Neuroleptics in progressive structural brain abnormalities in psychiatric illness. [Research letters]. Lancet, 352(9130):784-785, 1998.
25. Matthews, S.M.; Roper, M.T.; Mosher, L.R.; and Menn, A.Z. A non-neuroleptic treatment for schizophrenia: Analysis of the two-year postdischarge risk of relapse. Schizophrenia Bulletin, 5(2):322-333, 1979.
26. May, P.R.A.; Tuma, A.H.; and Dixon, W.J. Schizophrenia: A follow-up study of the results of five forms of treatment. Archives of General Psychiatry, 38:776-784, 1981.
27. Mosher, L.R., and Menn, A.Z. Community residential treatment for schizophrenia: Two-year follow-up. Hospital and Community Psychiatry, 29(11):715-723, 1978a.
28. Mosher, L.R., and Menn, A.Z. Enhancing psychosocial competence in schizophrenia: Preliminary results of the Soteria project. In: Fann, W.E.; Carcan, I.C.; Pokorney, A.; and Williams, R.L., eds. Phenomenology and Treatment of Schizophrenia. Jamaica, NY: Spectrum Publications, 1978b. pp. 371-386.
29. Mosher, L.R.; Vallone, R.; and Menn, A. The treatment of acute psychosis without neuroleptics: Six-week psychopathology outcome data from the Soteria project. International Journal of Social Psychiatry, 41(3):157-173, 1995.
30. Popp, S.M., and Trezza, G.R. Side effects of and reactions to psychotropic medications. In: Kleespies, P.M., ed. Emergencies in Mental Health Practice. New York, NY: Guilford, 1998. pp. 279-311.
31. Rappaport, M.; Hopkins, H.K.; Hall, K.; Belleza, T.; and Silverman, J. Are there schizophrenics for whom drugs may be unnecessary or contraindicated? International Pharmacopsychiatry, 13(2):100-111, 1978.
32. Robins, E., and Guze, S.B. Establishment of diagnostic validity in psychiatric illness: Its application to schizophrenia. American Journal of Psychiatry, 126(7):107-111, 1970.
33. Schooler, N.R.; Goldberg, S.C.; Boothe, H.; and Cole, J.O. One year after discharge: Community adjustment of schizophrenic patients. American Journal of Psychiatry, 123(8):986-995, 1967.
34. Sernyak, M.J.; Leslie, D.L.; Alarcon, R.D.; Losonczy, M.F.; and Rosenheck, R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159(4):561-566, 2002.
35. Snow, R.E. Aptitude-treatment interaction as a framework for research on individual differences in psychotherapy. Journal of Consulting and Clinical Psychology, 59(2):205-216, 1991.
36. Sternberg, R.J. Matching abilities, instruction and assessment: Reawakening the sleeping giant of ATI. In: Dennis, I., and Tapsfield, P., eds. Human Abilities: Their Nature and Measurement. Mahwah, NJ: Lawrence Erlbaum Associates, 1996. pp. 167-181.
37. Wahlbeck, K.; Tuunainen, A.; Ahokas, A.; and Leucht, S. Dropout rates in randomized antipsychotic drug trials. Psychopharmacology, 155:230-233, 2001.
38. Worrel, J.A.; Marken, P.A.; Beckman, S.E.; and Ruehter, V.L. Atypical antipsychotic agents: A critical review. American Journal of Health-System Pharmacy, 57(3):238-258, 2000.